CR20120502A - Uso de nuevos inhibidores de pan-cdk para tratar tumores - Google Patents
Uso de nuevos inhibidores de pan-cdk para tratar tumoresInfo
- Publication number
- CR20120502A CR20120502A CR20120502A CR20120502A CR20120502A CR 20120502 A CR20120502 A CR 20120502A CR 20120502 A CR20120502 A CR 20120502A CR 20120502 A CR20120502 A CR 20120502A CR 20120502 A CR20120502 A CR 20120502A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treat tumors
- cdk inhibitors
- new pan
- pan
- new
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere al uso de derivados seleccionados de anilinopirimidina sustituidos con sulfoximina de la fórmula (I) para tratar tumores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010014426A DE102010014426A1 (de) | 2010-04-01 | 2010-04-01 | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120502A true CR20120502A (es) | 2012-11-20 |
Family
ID=43858236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120502A CR20120502A (es) | 2010-04-01 | 2012-10-01 | Uso de nuevos inhibidores de pan-cdk para tratar tumores |
Country Status (20)
Country | Link |
---|---|
US (1) | US20130210846A1 (es) |
EP (1) | EP2552450A1 (es) |
JP (1) | JP5816259B2 (es) |
KR (1) | KR20130014678A (es) |
CN (1) | CN102834100A (es) |
AU (1) | AU2011234654B2 (es) |
BR (1) | BR112012024422A2 (es) |
CA (1) | CA2794996A1 (es) |
CL (1) | CL2012002753A1 (es) |
CR (1) | CR20120502A (es) |
DE (1) | DE102010014426A1 (es) |
DO (1) | DOP2012000260A (es) |
EC (1) | ECSP12012198A (es) |
MA (1) | MA34098B1 (es) |
MX (1) | MX337722B (es) |
NZ (1) | NZ602710A (es) |
SG (2) | SG10201502566SA (es) |
TN (1) | TN2012000469A1 (es) |
UA (1) | UA108494C2 (es) |
WO (1) | WO2011120922A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150051232A1 (en) * | 2012-03-21 | 2015-02-19 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
CA2904149A1 (en) * | 2013-03-07 | 2014-09-12 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours |
CN105530937A (zh) * | 2013-03-13 | 2016-04-27 | 昂克希尔迪克斯有限公司 | 使用7-苄基-10-(2-甲基苄基)-2,6,7,8,9,10-六氢咪唑并[1,2-a]吡啶并[4,3-d]嘧啶-5(3h)-酮的联合疗法 |
WO2014173815A1 (en) * | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
WO2014202583A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
WO2015071231A1 (de) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren |
CN109283279B (zh) * | 2017-07-21 | 2019-11-01 | 南京正大天晴制药有限公司 | 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法 |
CN109283263B (zh) * | 2017-07-21 | 2019-06-25 | 南京正大天晴制药有限公司 | 用于雷替曲塞合成质量控制的检测分析方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
ATE336484T1 (de) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | Pyrimidine verbindungen |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
EP1392662B1 (de) | 2001-05-29 | 2009-01-07 | Bayer Schering Pharma Aktiengesellschaft | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
EP1483260A1 (de) | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
EP2179991A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2010
- 2010-04-01 DE DE102010014426A patent/DE102010014426A1/de not_active Withdrawn
-
2011
- 2011-03-28 MA MA35265A patent/MA34098B1/fr unknown
- 2011-03-28 CA CA2794996A patent/CA2794996A1/en not_active Abandoned
- 2011-03-28 SG SG10201502566SA patent/SG10201502566SA/en unknown
- 2011-03-28 JP JP2013501789A patent/JP5816259B2/ja not_active Expired - Fee Related
- 2011-03-28 MX MX2012011427A patent/MX337722B/es active IP Right Grant
- 2011-03-28 UA UAA201212233A patent/UA108494C2/uk unknown
- 2011-03-28 NZ NZ602710A patent/NZ602710A/en not_active IP Right Cessation
- 2011-03-28 AU AU2011234654A patent/AU2011234654B2/en not_active Ceased
- 2011-03-28 KR KR1020127025684A patent/KR20130014678A/ko not_active Application Discontinuation
- 2011-03-28 BR BR112012024422A patent/BR112012024422A2/pt not_active IP Right Cessation
- 2011-03-28 CN CN2011800166124A patent/CN102834100A/zh active Pending
- 2011-03-28 EP EP11710224A patent/EP2552450A1/de not_active Withdrawn
- 2011-03-28 US US13/638,833 patent/US20130210846A1/en not_active Abandoned
- 2011-03-28 SG SG2012065819A patent/SG183925A1/en unknown
- 2011-03-28 WO PCT/EP2011/054733 patent/WO2011120922A1/de active Application Filing
-
2012
- 2012-09-27 TN TNP2012000469A patent/TN2012000469A1/en unknown
- 2012-10-01 DO DO2012000260A patent/DOP2012000260A/es unknown
- 2012-10-01 CL CL2012002753A patent/CL2012002753A1/es unknown
- 2012-10-01 EC ECSP12012198 patent/ECSP12012198A/es unknown
- 2012-10-01 CR CR20120502A patent/CR20120502A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2011234654A1 (en) | 2012-10-25 |
DE102010014426A1 (de) | 2011-10-06 |
ECSP12012198A (es) | 2012-10-30 |
UA108494C2 (uk) | 2015-05-12 |
NZ602710A (en) | 2014-05-30 |
KR20130014678A (ko) | 2013-02-08 |
CL2012002753A1 (es) | 2013-01-18 |
SG183925A1 (en) | 2012-10-30 |
BR112012024422A2 (pt) | 2016-05-31 |
CN102834100A (zh) | 2012-12-19 |
TN2012000469A1 (en) | 2014-01-30 |
MX337722B (es) | 2016-03-16 |
JP2013523680A (ja) | 2013-06-17 |
CA2794996A1 (en) | 2011-10-06 |
DOP2012000260A (es) | 2013-03-31 |
MX2012011427A (es) | 2013-03-05 |
SG10201502566SA (en) | 2015-05-28 |
EP2552450A1 (de) | 2013-02-06 |
AU2011234654B2 (en) | 2015-08-06 |
WO2011120922A1 (de) | 2011-10-06 |
JP5816259B2 (ja) | 2015-11-18 |
US20130210846A1 (en) | 2013-08-15 |
MA34098B1 (fr) | 2013-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
CR20120502A (es) | Uso de nuevos inhibidores de pan-cdk para tratar tumores | |
EA201270149A1 (ru) | Ингибиторы bace | |
CR20130045A (es) | Compuestos terapéuticos | |
JO3515B1 (ar) | مثبطات fgfr4 بيريميدين | |
CR20140229A (es) | Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CR11776A (es) | Inhibidores de bace | |
EA201190227A1 (ru) | Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ | |
EA201590748A1 (ru) | Противовирусные соединения против rsv | |
EA201492056A1 (ru) | Пиримидиниловые ингибиторы тирозинкиназы | |
UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
CR20120295A (es) | Triazolopiridinas | |
BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
CR20120637A (es) | Triazolopiridinas sustituidas | |
CR20140135A (es) | Nuevos derivados de aril-quinolina | |
EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
EA201290642A1 (ru) | Соединения и способы | |
UA106889C2 (uk) | Похідні n1-ацил-5-фторпіримідинону | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
EA201590656A1 (ru) | Азаиндолины | |
EA201600002A1 (ru) | Производные пролекарства замещенных триазолопиридинов |